Replies to post #106174 on Biotech Values

[genisi]

Yes, that trial was halted and all patients were offered abiraterone. JNJ suppose to offer it to some more patients via an early-access program.

[iwfal]

FDA shenanigans - Abiraterone (Zytiga) :

AVII found some very fascinating mismatched dates between the FDA documentation for Zytiga approval and the J&J PRs etc.. The timeline seems to have gone like:

a) Jan 2010 (see dates in FDA Statistical Review): Pre-planned interim occurs for OS - Zytiga is VERY stat sig (<0.0001 when alpha was 0.0141).

b) Sept 2010: Final OS analysis for OS (kinda immaterial - but very stat sig)

c) Oct 2010: First J&J PR that they hit the interim (and thus x-over is allowed - but note PR is silent on the fact that they hit that interim 9 months ago).


And within the FDA Statistical Review you can find the reason:

The updated OS analysis was conducted per the Agency’s request to confirm the OS estimates. The cut-off date for the updated OS analysis was before the first subject crossing over